Blood Cancer
Showing 1–16 of 49 results
-
ADAKVEO (crizanlizumab-tmca) injection, for intravenous use. Initial U.S. Approval: 2019
Read more -
ALIQOPA (copanlisib) for injection, for intravenous use. Initial U.S. Approval: 2017
Read more -
ANDEXXA (coagulation factor Xa (recombinant), inactivated-zhzo). Lyophilized powder for solution for intravenous injection. Initial U.S. Approval: 2018
Read more -
Atriance (nelarabine) for injection
Read more -
BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use. Initial U.S. Approval: 2020
Read more -
BLINCYTO (blinatumomab) for injection, for intravenous use. Initial U.S. Approval: 2014
Read more -
BOSULIF (bosutinib) tablets
Read more -
BRUKINSA (zanubrutinib) capsules, for oral use. Initial U.S. Approval: 2019
Read more -
CALQUENCE (acalabrutinib) capsules, for oral use. Initial U.S. Approval: 2017
Read more -
Columvi (glofitamab) for injection
Read more -
COPIKTRA (duvelisib), capsules for oral use. Initial U.S. Approval: 2018
Read more -
COTELLIC (cobimetinib) tablets. FDA-Approved
Read more -
DARZALEX (daratumumab) injection, for intravenous use. Initial U.S. Approval – 2015
Read more -
DAURISMO (glasdegib) tablets
Read more -
ELREXFIO (elranatamab-bcmm) injection
Read more -
EMPLICITI (elotuzumab) for injection
Read more